Vanda Pharmaceuticals Inc... (VNDA)
| Bid | 3.7 |
| Market Cap | 255.13M |
| Revenue (ttm) | 198.77M |
| Net Income (ttm) | -18.9M |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | -13.26 |
| Forward PE | 144.83 |
| Analyst | Strong Buy |
| Ask | 4.92 |
| Volume | 115,844 |
| Avg. Volume (20D) | 708,098 |
| Open | 4.34 |
| Previous Close | 4.37 |
| Day's Range | 4.30 - 4.38 |
| 52-Week Range | 3.85 - 6.75 |
| Beta | 0.72 |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...
Analyst Forecast
According to 3 analyst ratings, the average rating for VNDA stock is "Strong Buy." The 12-month stock price forecast is $20, which is an increase of 357.14% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call TranscriptVanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, Presid...
